Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 204

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Open access
Dagogo-Jack, Ibiayi, Yoda, Satoshi, Lennerz, Jochen K., Langenbucher, Adam, Lin, Jessica J., Rooney, Marguerite M., Prutisto-Chang, Kylie, Oh, Audris, Adams, Nathaniel A., Yeap, Beow Y., Chin, Emily, Do, Andrew, Marble, Hetal D., Stevens, Sara E., Digumarthy, Subba R., Saxena, Ashish, Nagy, Rebecca J., Benes, Cyril H., Azzoli, Christopher G., Lawrence, Michael S., Gainor, Justin F., Shaw, Alice T., Hata, Aaron N. · 2020 · Clinical Cancer Research

Abstract

Purpose: Most ALK-positive lung cancers will develop ALK-independent resistance after treatment with next-generation ALK inhibitors. MET amplification has been described in patients progressing on ALK inhibitors, but frequency of this event has not been comprehensively assessed. Experimental Design: We performed FISH and/or next-generation sequencing on 207 posttreatment tissue (n = 101) or plasma (n = 106) specimens from patients with ALK-positive lung cancer to detect MET genetic alterations. We evaluated ALK inhibitor sensitivity in cell lines with MET alterations and assessed antitumor activity of ALK/MET blockade in ALK-positive cell lines and 2 patients with MET-driven resistance. Results: MET amplification was detected in 15% of tumor biopsies from patients relapsing on next-generation ALK inhibitors, including 12% and 22% of biopsies from patients progressing on second-generation inhibitors or lorlatinib, respectively. Patients treated with a second-generation ALK inhibitor in the first-line setting were more likely to develop MET amplification than those who had received next-generation ALK inhibitors after crizotinib (P = 0.019). Two tumor specimens harbored an identical ST7-MET rearrangement, one of which had concurrent MET amplification. Expressing ST7-MET in the sensitive H3122 ALK-positive cell line induced resistance to ALK inhibitors that was reversed with dual ALK/MET inhibition. MET inhibition resensitized a patient-derived cell line harboring both ST7-MET and MET amplification to ALK inhibitors. Two patients with ALK-positive lung cancer and acquired MET alterations achieved rapid responses to ALK/MET combination therapy. Conclusions: Treatment with next-generation ALK inhibitors, particularly in the first-line setting, may lead to MET-driven resistance. Patients with acquired MET alterations may derive clinical benefit from therapies that target both ALK and MET.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-3906

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 204

Metadata

Authors
Dagogo-Jack, I., Yoda, S., Lennerz, J. K., Langenbucher, A., Lin, J. J., Rooney, M. M., Prutisto-Chang, K., Oh, A., Adams, N. A., Yeap, B. Y., Chin, E., Do, A., Marble, H. D., Stevens, S. E., Digumarthy, S. R., Saxena, A., Nagy, R. J., Benes, C. H., Azzoli, C. G., Lawrence, M. S., Gainor, J. F., Shaw, A. T., & Hata, A. N.
Venue
Clinical Cancer Research
Published
2020-06-01
Volume
26
Issue
11
Pages
2535-2545
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3007665819
Cited by
204
References
10
FWCI
15.39
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-3906
The paper
Dagogo-Jack, I., Yoda, S., Lennerz, J. K., Langenbucher, A., Lin, J. J., Rooney, M. M., Prutisto-Chang, K., Oh, A., Adams, N. A., Yeap, B. Y., Chin, E., Do, A., Marble, H. D., Stevens, S. E., Digumarthy, S. R., Saxena, A., Nagy, R. J., Benes, C. H., Azzoli, C. G., . . . Hata, A. N. (2020). MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-3906

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.